CL2020002833A1 - Métodos para tratar cáncer - Google Patents

Métodos para tratar cáncer

Info

Publication number
CL2020002833A1
CL2020002833A1 CL2020002833A CL2020002833A CL2020002833A1 CL 2020002833 A1 CL2020002833 A1 CL 2020002833A1 CL 2020002833 A CL2020002833 A CL 2020002833A CL 2020002833 A CL2020002833 A CL 2020002833A CL 2020002833 A1 CL2020002833 A1 CL 2020002833A1
Authority
CL
Chile
Prior art keywords
methods
treat cancer
formula
mpn
therapeutic methods
Prior art date
Application number
CL2020002833A
Other languages
English (en)
Spanish (es)
Inventor
Wayne Rothbaum
Original Assignee
Kartos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kartos Therapeutics Inc filed Critical Kartos Therapeutics Inc
Publication of CL2020002833A1 publication Critical patent/CL2020002833A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2020002833A 2018-04-30 2020-10-30 Métodos para tratar cáncer CL2020002833A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862664673P 2018-04-30 2018-04-30
US201862701088P 2018-07-20 2018-07-20
US201862781942P 2018-12-19 2018-12-19
US201962834848P 2019-04-16 2019-04-16

Publications (1)

Publication Number Publication Date
CL2020002833A1 true CL2020002833A1 (es) 2021-04-30

Family

ID=68386769

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002833A CL2020002833A1 (es) 2018-04-30 2020-10-30 Métodos para tratar cáncer

Country Status (20)

Country Link
US (2) US12115153B2 (https=)
EP (1) EP3787625A4 (https=)
JP (2) JP2021523220A (https=)
KR (2) KR102849513B1 (https=)
CN (2) CN112512525A (https=)
AU (2) AU2019263064B2 (https=)
BR (1) BR112020022148A2 (https=)
CA (1) CA3098606A1 (https=)
CL (1) CL2020002833A1 (https=)
CO (1) CO2020014599A2 (https=)
CR (1) CR20200576A (https=)
IL (3) IL319432A (https=)
JO (1) JOP20200273A1 (https=)
MX (2) MX2020011608A (https=)
PE (1) PE20211653A1 (https=)
PH (1) PH12020551820A1 (https=)
SG (1) SG11202010793UA (https=)
TN (1) TN2020000210A1 (https=)
TW (3) TW202146387A (https=)
WO (1) WO2019213074A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022004225A2 (pt) * 2019-09-16 2022-05-31 Novartis Ag Uso de um inibidor de mdm2 para o tratamento de mielofibrose
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
CN113337602A (zh) * 2020-03-02 2021-09-03 苏州亚盛药业有限公司 Mdm2抑制剂的治疗方法和生物标志物
WO2022219128A1 (en) * 2021-04-15 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) In vitro tests allowing to identify the potential for mdm2 inhibitors to induce the selection of mutations in patients suffering from a myeloproliferative neoplasm
WO2023039160A1 (en) * 2021-09-09 2023-03-16 Kartos Therapeutics Methods of treating a cancer overexpressing one or more bcl-2 family proteins
US20250134877A1 (en) * 2021-09-09 2025-05-01 Kartos Therapeutics Methods of treating cancer dependent on myc gene expresssion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
RS59363B1 (sr) * 2012-12-07 2019-11-29 Geron Corp Upotreba inhibitora telomeraze imetelstata za lečenje mijelofibroze
WO2014134201A1 (en) 2013-02-28 2014-09-04 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
CN105358530A (zh) 2013-06-10 2016-02-24 美国安进公司 制备mdm2抑制剂的方法及其结晶形式
BR112016010564A2 (pt) * 2013-11-11 2017-10-10 Amgen Inc terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres
WO2015081127A2 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
CN105848656B (zh) 2013-12-23 2019-10-25 诺华股份有限公司 药物组合
IL286427B2 (en) * 2014-01-28 2024-08-01 Mayo Found Medical Education & Res Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor

Also Published As

Publication number Publication date
IL319432A (en) 2025-05-01
US20210186946A1 (en) 2021-06-24
TWI741286B (zh) 2021-10-01
IL308399B2 (en) 2025-08-01
SG11202010793UA (en) 2020-11-27
WO2019213074A1 (en) 2019-11-07
JP2021523220A (ja) 2021-09-02
CN120037232A (zh) 2025-05-27
KR102849513B1 (ko) 2025-08-25
KR20210019422A (ko) 2021-02-22
KR20250130704A (ko) 2025-09-02
PH12020551820A1 (en) 2021-07-26
BR112020022148A2 (pt) 2021-04-13
IL308399A (en) 2024-01-01
TW202529759A (zh) 2025-08-01
TW201945340A (zh) 2019-12-01
CO2020014599A2 (es) 2021-02-26
TN2020000210A1 (en) 2022-07-01
JOP20200273A1 (ar) 2020-11-01
AU2025201686A1 (en) 2025-03-27
MX2024003655A (es) 2024-04-15
JP2024050668A (ja) 2024-04-10
AU2019263064A1 (en) 2020-12-03
IL278345A (https=) 2020-12-31
MX2020011608A (es) 2021-02-17
TW202146387A (zh) 2021-12-16
PE20211653A1 (es) 2021-08-24
IL278345B1 (en) 2024-01-01
AU2019263064B2 (en) 2024-12-19
EP3787625A4 (en) 2022-01-26
EP3787625A1 (en) 2021-03-10
IL278345B2 (en) 2024-05-01
IL308399B1 (en) 2025-04-01
CR20200576A (es) 2021-04-30
US20250090517A1 (en) 2025-03-20
CA3098606A1 (en) 2019-11-07
CN112512525A (zh) 2021-03-16
US12115153B2 (en) 2024-10-15

Similar Documents

Publication Publication Date Title
CO2020014599A2 (es) Métodos para tratar cáncer
MX2022000711A (es) Inhibidores de parp1.
GEAP202516803A (en) Bicyclic amines as cdk2 inhibitors
MX2021013788A (es) Dosificación del inhibidor de kras para el tratamiento de cánceres.
MX2025002382A (es) Anticuerpos antagonistas anti-tigit y anti-pd-l1 y usos de los mismos para el tratamiento del cancer
SI3883579T1 (sl) Kombinirana terapija, ki vključuje zaviralec KRAS-G12C in eno ali več dodatnih farmacevtsko aktivnih sredstev za zdravljenje raka
GEAP202315703A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2018002924A1 (es) Inhibidores de bromodominios
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
EA201690980A1 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
EA201892510A2 (ru) Комбинированная терапия для лечения рака
MX391720B (es) Terapia combinada para tratar cáncer.
CO2020015923A2 (es) Antagonista de gremlin-1 para la prevención y tratamiento del cáncer
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CY1124613T1 (el) Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης
MX2025009369A (es) Inhibidores de mdm2 para usarse en el tratamiento de neoplasias mieloproliferativas
MX2020009773A (es) Terapia de combinacion.
MX2019003134A (es) Terapia de combinacion.
CY1124123T1 (el) Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου
MX2020012826A (es) Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
MX2021001612A (es) Compuestos utiles en terapia del vih.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
CR20220374A (es) Métodos de tratamiento de la esplenomegalia